Botanicals have been used for medicinal purposes long before recorded history. Ancient Chinese and Egyptian papyrus writings describe medicinal uses for plants as early as 3,000 BC. Indigenous cultures (such as African and Native American) used herbs in their healing rituals, while others developed traditional medical systems (such as Ayurveda and Traditional Chinese Medicine) in which herbal therapies were used. Researchers found that people in different parts of the world tended to use the same or similar plants for the same purposes validating the use of several botanicals.
In the early 19th century, when chemical analysis first became available, scientists began to extract and modify the active ingredients from plants. Almost one fourth of pharmaceutical prescription drugs today is originally or was structurally derived from botanicals.
Recently, the World Health Organization estimated that 80% of people worldwide rely on herbal medicines for some part of their primary health care. In Germany alone, about 700 plant-based medicines are available and are prescribed by some 70% of German physicians. Echinacea purpurea is one of the most commonly used botanical products alone or in combination because it is believed to stimulate natural immunity.
Control of the inflammatory response and tissue repair are major therapeutic challenges encompassing a wide range of medical conditions. Existing treatments for multi-billion dollar markets in wound care, oncology support, women’s care, gastrointestinal disease, oral care and dermatological care provide, at best, only partial relief. In addition to seeking more comprehensive treatments, pharmaceutical companies are searching for safe and effective solutions that encompass natural ingredients to provide breakthrough technologies that will address indications that are under-served by the products that are currently available.
Izun Pharmaceuticals Corporation (“IPC” or “Izun”) was founded in 2000 with the initial goal of providing an effective natural solution in the area of periodontal inflammation. A proprietary, botanically-based platform technology was developed which helps treat a wide range of inflammatory diseases, while simultaneously accelerating the body’s natural tissue repair processes. Izun’s products are both efficacious and safe, providing novel solutions with the potential to capitalize on multi-billion-dollar market opportunities. Izun’s natural based products also enable multiple options with regard to regulatory filings and speedier approvals.
- recently received FDA approval of Curasite, a novel wound care therapy,
- successfully concluded a double-blinded placebo controlled Phase II clinical trial for the prevention of oral mucositis, a common side effect of chemotherapy and radiation therapy,
- recently completed a Phase IIa clinical trial in the areas of Women’s Healthcare which demonstrated a dramatic reduction in the symptoms of post-menopausal Vulvovaginal Atrophy (VVA),
- and launched two oral care products, one aimed at the professional dental care market and one for the OTC market.
Results of all these trials are extremely exciting as we move ahead with plans for commercialization of these products.
Izun’s IP portfolio consists of over 65 patents, of which more than 35 have been granted.
Izun is a US corporation incorporated under the laws of Delaware, with a wholly-owned Jerusalem-based R&D subsidiary employing a staff of 17. In addition to an experienced and accomplished management team, Izun is supported by a world-class Board of Directors and a team of scientific advisors and key opinion leaders.
The Company’s quality policy is to develop products of excellence that fully meet applicable good manufacturing practices (cGMP). As an ISO-certified company, this is achieved by designing, maintaining, assessing, improving and implementing an overall quality assurance system.
In addition, it is the Company’s policy to encourage its employees always to strive for excellence and for continual improvement. To this end, the Company conducts ongoing training for all employees, improving employee understanding of work processes, increasing the professional knowledge and awareness of employees in all areas of the Company’s activities and reinforcing the Company’s policy of striving for excellence in all aspects of its work.
Reliability is a vital cornerstone of the Company’s business policy and development of innovative quality products is the primary objective of the Company staff. The Company recognizes that its staff and their knowledge, experience, and professionalism are a vital part of the Company and the means by which its business policy can be achieved. Verification and control of quality are carried out by continuous assessment using fully documented procedures and records.
The Company operates within the requirements of the law and monitors changes to those requirements so that they can be implemented in a timely manner. Similarly, adherence to relevant local and international standards is implemented.
In order to improve Company products and increase efficiency, Company procedures include corrective and preventive actions and continual lesson-learning, by dealing promptly and effectively with any requests or queries received. The effectiveness of these activities is monitored and Company staff receives regular training on procedures and updates thereof. An internal audit program is carried out to verify correct implementation of procedures and their conformance to the requirements of ISO 9001 and ISO 13485.
Izun Pharmaceuticals Corporation (IPC) is a privately held Delaware-based corporation with headquarters in New York City and a research and development facility in Israel. The Company was founded in 2000 by William Z. Levine, DDS.
Since its inception, the Company has been funded by high net worth individuals and other qualified investors who believe in the collective power of botanically-based medicine to meet urgent health care needs while maintaining a premium on patient safety. The technology of the company has been validated by several approvals in the United States and Europe and continues to show promise in recent and ongoing clinical trials.
Interested parties in discussing a potential investment should contact Mr. Jack Talley at email@example.com or at +1-203-895-1524.